Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00445601 | S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer | completed | Phase 3 | 406 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 18, 2020 | clinicaltrials |
| NCT02260817 | Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer | completed | Phase 3 | 109 | Global Isotopes, LLC d/b/a Zevacor MolecularINDUSTRY | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00001806 | Methods in Education for Breast Cancer Genetics | completed | Phase 3 | 170 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01715129 | Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer(DKP 3M SC) | completed | Phase 3 | 126 | IpsenINDUSTRY | 5 | Dec 9, 2019 | clinicaltrials |
| NCT02918357 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence(PSMA BCR) | completed | Phase 2 / Phase 3 | 385 | University of California, San FranciscoOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT03158220 | Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004) | completed | Phase 3 | 1,212 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | Oct 28, 2019 | clinicaltrials |
| NCT02578940 | Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer(FALCON) | completed | Phase 3 | 104 | Blue Earth DiagnosticsINDUSTRY | 1 | Oct 7, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT01629563 | PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata(PEARLIV) | completed | Phase 3 | 451 | PregLem SAINDUSTRY | 11 | Sep 4, 2019 | clinicaltrials |
| NCT02660190 | Photodynamic Diagnosis (PDD) in Flexible Cystoscopy(DaBlaCa-11) | completed | Phase 3 | 696 | Jørgen Bjerggaard JensenOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT04056754 | Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer | completed | Phase 3 | 268 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02302807 | A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] | completed | Phase 3 | 931 | Hoffmann-La RocheINDUSTRY | 29 | Aug 1, 2019 | clinicaltrials |
| NCT00041080 | Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 3 | 139 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00262847 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 1,873 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT00803062 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | completed | Phase 3 | 452 | National Cancer Institute (NCI)NIH | 2 | Jul 23, 2019 | clinicaltrials |
| NCT01695135 | A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy | completed | Phase 3 | 214 | Janssen Research & Development, LLCINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT01310894 | Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.(PCM301) | completed | Phase 3 | 413 | Steba Biotech S.A.OTHER | 10 | Jul 11, 2019 | clinicaltrials |
| NCT01006395 | Prevention of Micro-architectural Bone Decay in Males With Non-metastatic Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) | completed | Phase 2 / Phase 3 | 64 | Austin HealthOTHER_GOV | 1 | Jul 5, 2019 | clinicaltrials |
| NCT02085252 | A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer | completed | Phase 3 | 116 | TakedaINDUSTRY | 1 | Jun 28, 2019 | clinicaltrials |
| NCT00003779 | Biological Therapy in Treating Patients With Bladder Cancer | completed | Phase 3 | 40 | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT00770874 | Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer | completed | Phase 3 | 375 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 3 | Jun 21, 2019 | clinicaltrials |
| NCT00255125 | Role of Soy Supplementation in Prostate Cancer Development | completed | Phase 3 | 86 | VA Office of Research and DevelopmentFED | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01308567 | Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer(FIRSTANA) | completed | Phase 3 | 1,168 | SanofiINDUSTRY | 25 | Jun 5, 2019 | clinicaltrials |
| NCT00003644 | Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer | completed | Phase 3 | 571 | Gynecologic Oncology GroupNETWORK | 2 | Jun 4, 2019 | clinicaltrials |
| NCT02355886 | Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy | completed | Phase 2 / Phase 3 | 25 | University of WashingtonOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT00003214 | Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer | completed | Phase 3 | 300 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT01707966 | Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy | completed | Phase 3 | 47 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02935530 | Thromboprophylaxis After Surgery for Gynecologic Malignancy in China | completed | Phase 3 | 315 | Huazhong University of Science and TechnologyOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT00011986 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 3 | 4,312 | Gynecologic Oncology GroupNETWORK | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02615067 | Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer(proSPECT-AS) | completed | Phase 3 | 531 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 2 | Apr 10, 2019 | clinicaltrials |
| NCT01846611 | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 581 | Janssen Research & Development, LLCINDUSTRY | 10 | Apr 1, 2019 | clinicaltrials |
| NCT02712320 | Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg | completed | Phase 3 | 30 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 26, 2019 | clinicaltrials |
| NCT02655224 | A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids | completed | Phase 3 | 65 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT02655237 | A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids | completed | Phase 3 | 281 | TakedaINDUSTRY | 1 | Mar 22, 2019 | clinicaltrials |
| NCT00096408 | Laparoscopic Approach to Cancer of the Endometrium | completed | Phase 3 | 760 | Queensland Centre for Gynaecological CancerOTHER_GOV | 4 | Mar 20, 2019 | clinicaltrials |
| NCT00128661 | Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants | completed | Phase 3 | 7,466 | GlaxoSmithKlineINDUSTRY | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02234115 | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma | completed | Phase 3 | 137 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 8 | Mar 5, 2019 | clinicaltrials |
| NCT01376349 | Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms | completed | Phase 3 | 464 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2019 | clinicaltrials |
| NCT00365989 | MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication | completed | Phase 3 | 50 | InSightecINDUSTRY | 2 | Feb 5, 2019 | clinicaltrials |
| NCT01020448 | Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer(Triptocare) | completed | Phase 3 | 339 | IpsenINDUSTRY | 10 | Jan 30, 2019 | clinicaltrials |
| NCT02680041 | 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment(LOCATE) | completed | Phase 3 | 221 | Blue Earth DiagnosticsINDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT00678392 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | completed | Phase 3 | 723 | PfizerINDUSTRY | 22 | Jan 9, 2019 | clinicaltrials |
| NCT00867347 | Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer | completed | Phase 3 | 45 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT00295217 | MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation | completed | Phase 3 | 15 | InSightecINDUSTRY | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01193257 | Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. | completed | Phase 3 | 1,099 | Millennium Pharmaceuticals, Inc.INDUSTRY | 14 | Dec 19, 2018 | clinicaltrials |
| NCT00974311 | Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy(AFFIRM) | completed | Phase 3 | 1,199 | PfizerINDUSTRY | 15 | Dec 11, 2018 | clinicaltrials |
| NCT00068692 | Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer | completed | Phase 3 | 225 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2018 | clinicaltrials |
| NCT00087022 | Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer | completed | Phase 3 | 864 | Heidelberg Pharma AGINDUSTRY | 4 | Nov 27, 2018 | clinicaltrials |
| NCT00543543 | Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) | completed | Phase 3 | 14,840 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jan 18, 2020source: clinicaltrials